Condition Directory

Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Cancer. Browse Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced July 23, 2026 Report an issue

ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

14815

Shown on this page

Current sort

How Cancer studies are organized in the registry

“Cancer” is the broadest term in the registry, and most oncology records list a specific cancer type rather than the umbrella word. If you are researching a particular diagnosis, the dedicated pages for that cancer type usually give a cleaner result set. Tumor-agnostic and basket studies are the exception — they often appear under generic terms instead of a single organ site.

Terms that often appear in related listings

solid tumor advanced solid tumors metastatic basket trial

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 14,815 matching trials for Cancer.

Live ClinicalTrials.gov results.

Active filters: "metastatic" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: Pheochromocytoma, Endocrine Disease, Endocrine Diseases
Interventions: ([18F]-DOPA), ([18F]-6F-DA); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Years to 120 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2048
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Interventions: INCA33890, bevacizumab, FOLFIRI, FOLFOX, Cetuximab, ADG126; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 7 more

Conditions: Advanced Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Interventions: Zolbetuximab, mFOLFOX6, CAPOX; Drug
Lead sponsor: Midhun Malla; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
Interventions: Arm 1; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sarcoma
Interventions: Non-Metastatic and Resectable, Metastatic and Un-resectable, No evidence of disease, under surveillance, ALT or WDLS; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Advanced Solid Tumors
Interventions: M3T01, Pembrolizumab, Chemoradiation, FOLFOX regimen; Drug · Radiation
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions: SERD* + abemaciclib, SERD* + everolimus, SERD* + everolimus or capecitabine, SOC, Antiandrogen; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Baltimore, Maryland • Rochester, Minnesota • Chapel Hill, North Carolina

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Carcinoma of Larynx, Oral Squamous Cell Carcinoma, Salivary Gland Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions: SX-682, DTX; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Interventions: MRTX849, Cetuximab, mFOLFOX6 Regimen, FOLFIRI Regimen; Drug · Biological
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 185
States / cities: Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 122 more

Conditions: Prostate Cancer, Radiation Toxicity, Urinary Complication
Interventions: Lisinopril Tablets; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
Interventions: BGB-43395, Fulvestrant, Letrozole, Elacestrant, Anti-Diarrheal Agent; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 10
States / cities: Denver, Colorado • Lake Mary, Florida • Detroit, Michigan + 7 more

Conditions: Pancreatic Neoplasms, Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms, Adenocarcinoma
Interventions: Gemcitabine, nab-paclitaxel, Pharmacological ascorbate; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

About this Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Cancer clinical trials

How Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Diagnosis of Pheochromocytoma

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Zolbetuximab With mFOLFOX6 or CAPOX in Claudin 18.2 Overexpressed Advanced or Metastatic Biliary Tract Cancers

Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases

LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)

About this Cancer clinical trials directory page